About
Leap Therapeutics is focused on developing targeted and immuno-oncology therapeutics.
Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. DKN-01 is in clinical trials in patients with esophagogastric, colorectal, gynecologic, and prostate cancers. Leap has entered into a strategic partnership with BeiGene, Ltd. for the rights to develop DKN-01 in Asia (excluding Japan), Australia, and New Zealand.
Our team

Christopher Mirabelli, PhD
Chairman of the Board

Douglas Onsi
President & CEO

Gus Lawlor
Chief Operating Officer

Cyndi Sirard, MD
Chief Medical Officer

Mark O’Mahony
Chief Manufacturing Officer

Walter Newman, PhD
Senior Research Fellow

Jason Baum, PhD
Vice President and Head of Translational Medicine

Christine Granfield
Vice President, Regulatory and Quality

Kevin Lloyd
Vice President, Program and Alliance Management
Board of directors
Christopher Mirabelli, PhD
Chairman of the Board, Leap Therapeutics
James Cavanaugh, PhD
Managing Director at HealthCare Ventures
Thomas Dietz, PhD
Chairman and CEO of Waypoint Holdings
William Li, MD
CEO and President of Angiogenesis Foundation
Douglas Onsi
President & CEO, Leap Therapeutics
Joseph Loscalzo, MD, PhD, MA
Chairman, Department of Medicine, Physician-in-Chief, Brigham and Women’s Hospital
Nissim Mashiach
Co-Founder of NuBiyota
Richard L. Schilsky, M.D., FACP, FSCT, FASCO
Fellow of the American College of Physicians, Fellow of the Society for Clinical Trials, and a Fellow of the American Society of Clinical Oncology.
Patricia Martin, MBA
Patricia Martin, MBA. Director. President & CEO of BioCrossroads
Scientific advisory board
David Tuveson, MD, PhD
Chair of Leap SAB, Director of Research, the Lustgarten Foundation, Roy J. Zuckerberg Professor of Cancer Research at Cold Spring Harbor Laboratory
Carl F. Nathan, MD
Professor and Chairman of Department of Microbiology and Immunology at Weill Cornell Medical College
Xi He, PhD
Endowed Research Chair, Professor of Neurology, American Cancer Society Research Professor, Boston Children’s Hospital and Harvard Medical School
Andrew B Nixon, PhD, MBA
Professor of Medicine at Duke University Medical Center, Director of the Phase I Biomarker Laboratory and Associate Director of the Duke Center for Cancer Immunotherapy
Richard Gaynor, MD
President and Chief, Research and Development, at BioNTech US; Scientific Advisory Committee for Stand up to Cancer; Board of Directors of the Damon Runyon Cancer Research Foundation, Alkermes plc. and Infinity Therapeutics
Eileen M. O’Reilly, MD
Winthrop Rockefeller Endowed Chair in Medical Oncology at Memorial Sloan Kettering (MSK), Section Head for Hepatopancreaticobiliary/ Neuroendocrine Cancers, Gastrointestinal Oncology Service, Co-Director for Medical Initiatives at the David M. Rubenstein Center for Pancreatic Cancer, Attending Physician and Member at MSK and Professor of Medicine at Weill Cornell Medical College